Story
Argentina is joining the Chinese coronavirus vaccine trial, says the manufacturer.
Argentina joined Peru, Morocco and the United Arab Emirates in the approval of phase 3 clinical trials for coronavirus vaccine developed by China National Biotec Group (CNBG), which was announced late Friday.
As China moves forward in the global race to develop a vaccine to curb the COVID-19 pandemic and as cases within China are declining, CNBG needs research participants from other countries to be tested.
Phase 3 trials, usually involving several thousand participants, allow researchers to collect data on the efficacy of potential vaccines for final regulatory approvals.
CNBG will be partnering with Argentina's ELEA in the vaccine trial, the Chinese company said late Friday in a statement.
CNBG, a state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm) experimental vaccine, received approval from the UAE for a Phase 3 trial in June and has since recruited 15,000 volunteers.
The company stated on Thursday that the trials were also approved by Peru and Morocco.
CNBG has also obtained approval from Bahrain for a Phase 3 study designed to involve some 6,000 participants.
